Launched in July 2018, the French Tech Seed fund is endowed with 400 million euros and managed by BpiFrance. This fund is intended to support Deep-Tech startups. Signia Therapeutics will benefit from an investment by the French Tech Seed fund to complement its current fundraising.
Our last review on drug repurposing approaches for the treatment of influenza viral infection has been accepted in Frontiers in Immunology.
Results from our collaboration with ICBMS/GEMBAS on SPRi-based hemagglutinin quantitative assay for influenza vaccine production monitoring have been published in Vaccine.
We hereby report an imaging surface plasmon resonance (SPRi) assay for the quantification of both inactivated vaccine influenza antigens and viral particles derived from egg- and cell-based production samples, respectively.
Our publication on the repurposing of Diltiazem as an innovative host targeted influenza inhibitor has been published in Frontiers in Immunology.
Licensed to Signia Therapeutics, Diltiazem is currently evaluated in a phase II clinical trial for the treatment of patients with severe influenza infections in intensive care units (FLUNEXT TRIAL PHRC #15-0442-ClinicalTrials.gov identifier NCT03212716).
Our publication in Journal of Virolgy concerning the functional interactions of cellular p53 and CPSF4 factors with NS1 and their impact on Influenza A virus replication.
Results from our collaborative ANR project OPTIVAC have been published in NPJ Vaccines.
Signia Therapeutics is highlighted in the innovation newsletter of the Centre National de Recherche Scientifique (CNRS), as an innovative start-up working on drug repurposing to counteract respiratory infections.
Andrés Pizzorno' article "Fighting the damocles sword of infectious diseases through drug repurposing" was published in European Biopharmaceutical Review (EBR).